In exemplary embodiments, the disclosure provides a Colesevelam Colon Specific Drug Delivery System for use in treatment of, for example, cholestasis and/or cholestatic pruritus.

A press coated tablet for delayed release of an active ingredient comprising: (a) a core comprising one or more active ingredients, and; (b) an erodible delayed release barrier surrounding the core and comprising a wax and two or more grades of L-HPC, wherein the wax and L-HPC are provided in a weight ratio of wax to L-HPC of from 30%:70% to 70%:30%. The invention also relates to a method of making the press coated tablet.

Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

Drug delivery formulations, uses thereof and methods of making same are provided in order to reduce the potential for abuse, misuse or improper administration of an addictive substance or any active substance and to prevent, reduce, inhibit, or delay purposeful or accidental overdose of an active substance by ingesting too many dosage forms at once, for example.

The presently disclosed subject matter relates to a composition and method of using the composition for oral delivery of a bioactive agent to a subject. More particularly, the presently disclosed subject matter relates to a composition comprising an effective amount of at least one bioacitve agent layered over a substrate and a method of reducing zoonotic infectious disease by administering the composition to a subject. The presently disclosed subject matter further relates to a method of preparing the composition.

Disclosed is a coating composition including, in relation to 100% of the weight thereof: 10-90 wt. % of at least one film-forming polymer selected from methyl cellulose, hydroxy propyl methyl cellulose, hydroxy propyl cellulose, hydroxy ethyl cellulose, sodium carboxy methyl cellulose, ethyl cellulose, PVA (polyvinyl alcohols), PVA-PEG (polyethylene glycol) copolymers, polyvinyl acetate, polyvinyl pyrrolidones (PVP), vinylpyrrolidone-vinyl acetate copolymers, alginates, pectin, arabic gum, guar gum, carrageenans, xanthan gum, inulin, chitosan, methacrylic acid copolymer, ethyl acetate, or polyethylene glycol-polypropylene glycol (PEG-PPG) copolymer; 0-50 wt. % of at least one auxiliary coating agent selected from diluents, surfactants, plasticisers and anti-foaming agents; and 10-50 wt. % of a whitening filler free of titanium dioxide including at least one alkaline or alkaline earth salt of a fatty acid and at least one cellulose compound selected from cellulose, cellulose powder, microcrystalline cellulose, or a mixture of the components.

The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.

The present invention relates to a complex preparation comprising clopidogrel, an HMG-CoA reductase inhibitor, and a separation membrane containing a hydrophobic compound. More particularly, an objective of the present invention is to provide the complex preparation comprising clopidogrel and the HMG-CoA reductase inhibitor, wherein the complex preparation is intended for preventing or treating a cardiovascular disease, which has excellent storage stability by preventing a decrease in the stability of the HMG-CoA reductase inhibitor.

The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms.

Provided is a pharmaceutical composition which contains pemafibrate, a salt thereof or a solvate thereof and one or more selected from the group consisting of a metal oxide, a dihydric alcohol, an ester species and a silicic acid compound and which has excellent storage stability. The pharmaceutical composition includes the following components (A) and (B): (A) pemafibrate, a salt thereof or a solvate thereof; and (B) one or more selected from the group consisting of the following components (B-1) to (B-4): (B-1) a metal oxide; (B-2) a dihydric alcohol; (B-3) an ester species; and (B-4) a silicic acid compound, with component (A) and component (B) being substantially in non-contact with each other.